DermaSensor raises $5M, opens skin-cancer device round to the public

What's the deal? DermaSensor, a Miami-based maker of an AI-powered skin cancer diagnostic device, has raised $5 million as it extends its Series B and opens the round to retail investors via Wefunder. The financing includes a $4 million extension from institutional and strategic backers, plus more than $1 million already raised from the public at the same terms.

What's the endgame? The company's handheld device, developed at Boston UniversityDealroom has a profile for this one. Try Dealroom →, uses elastic scattering spectroscopy and artificial intelligence to deliver an immediate risk result for suspicious skin lesions. In published studies, it showed 96% device sensitivity across melanoma, basal cell carcinoma, and squamous cell carcinoma, while cutting missed skin cancer referrals by more than half.

Why the crowd? Chief executive officer and co-founder Cody Simmons framed the Wefunder round as extending ownership beyond professional investors. "We want the people closest to it to have a seat at the table," he said, noting that one in five Americans are affected by skin cancer.

What else? DermaSensor announced four new US partnerships to widen distribution across primary care, enterprise healthcare, and federal systems. These include an approved supplier relationship with Henry ScheinDealroom has a profile for this one. Try Dealroom →, a commercial partnership with contract sales firm MedTech MedCareDealroom has a profile for this one. Try Dealroom →, a customer deal with a major US healthcare institution, and a reseller agreement with Medical PlaceDealroom has a profile for this one. Try Dealroom → covering the Department of Veterans AffairsDealroom has a profile for this one. Try Dealroom →.

By the numbers. The round follows a $16 million Series B closed in 2025 and brings total investment in the company to $48 million. The device launched commercially two years ago and has since scanned more than 45,000 lesions across hundreds of provider organisations.

The signal: DermaSensor is building commercial infrastructure to scale a newly created diagnostic category nationwide. Pairing institutional capital with a public raise and four distribution deals signals a push from clinical validation toward mainstream adoption.

Read more: morningstar.com

Image credit: Generated with Gemini